Experimental cancer drug trial halted early

NCT ID NCT05229601

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 25 times

Summary

This early-stage study tested a new drug called HFB301001 in 31 adults with advanced solid tumors (like sarcoma, kidney cancer, or melanoma) that had not responded to prior treatments. The main goal was to check the drug's safety and find the best dose. The study was terminated early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Hospital Clinico Universitario de Valencia

    Valencia, 46010, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, 28041, Spain

  • Hospital Universitario Vall d'Hebron

    Barcelona, 08035, Spain

  • Mayo Clinic

    Scottsdale, Arizona, 85259, United States

  • Mayo Clinic

    Jacksonville, Florida, 32224, United States

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

  • NEXT Virginia Cancer Specialists

    Fairfax, Virginia, 22031, United States

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California, 90033, United States

  • University of Maryland

    Baltimore, Maryland, 21201, United States

Conditions

Explore the condition pages connected to this study.